Adjuvant Chemotherapy Not Recommended for This Patient
This 60-year-old man with T3N0 (stage II) MSI-H colon cancer should NOT receive adjuvant chemotherapy. 1
Primary Recommendation Based on MSI-H Status
Patients with mismatch repair deficiency/microsatellite instability (MSI-H) tumors should not be routinely offered adjuvant chemotherapy in stage II colon cancer. 1
The 2022 ASCO guideline explicitly states that MSI-H status is a contraindication to routine adjuvant chemotherapy in stage II disease, as these tumors do not respond well to standard fluoropyrimidine-based regimens. 1
MSI-H colorectal cancers have better stage-adjusted survival compared to microsatellite stable tumors and do not benefit from 5-fluorouracil-based adjuvant chemotherapy. 2, 3
Risk Stratification Analysis
High-Risk Features Present:
- T3 tumor with invasion into pericolonic adipose tissue - This is NOT classified as T4, which is the primary high-risk feature that would mandate chemotherapy consideration. 1
- Adequate lymph node sampling - 12 lymph nodes were examined (meeting the minimum threshold), so this is NOT a high-risk feature. 1
High-Risk Features Absent:
- No T4 tumor (the strongest indication for adjuvant chemotherapy in stage II disease) 1
- No perineural or lymphovascular invasion mentioned 1
- Moderately differentiated (not poorly or undifferentiated) 1
- No intestinal obstruction or perforation 1
- Negative margins (R0 resection) 1
- All 12 lymph nodes negative 1
Critical Caveat About MSI-H and Chemotherapy
If the combination of MSI-H status and multiple high-risk factors resulted in a decision to offer chemotherapy (which does NOT apply to this patient), oxaliplatin-containing chemotherapy would be recommended rather than fluoropyrimidine alone. 1 However, this patient lacks the high-risk features that would justify this approach.
Prognosis and Surveillance
MSI-H tumors represent approximately 15% of all colorectal cancers and have distinct favorable prognostic features including better stage-adjusted survival. 2, 3
The presence of MSI-H with T3N0 disease and adequate lymph node sampling indicates a relatively favorable prognosis without chemotherapy. 3, 4
Standard surveillance with colonoscopy and imaging per guidelines is appropriate. 1
Why Chemotherapy Would Be Harmful
Stage II MSI-H tumors specifically do not benefit from fluorouracil-based adjuvant chemotherapy and may even have worse outcomes with such treatment. 3, 4
The molecular profile of MSI-H tumors (deficient mismatch repair, high mutational burden, strong immune infiltration) makes them resistant to conventional cytotoxic chemotherapy. 2, 4